Earnings call transcripts

Management framed the IND filing as a transition from Wnt platform science to clinical validation, emphasizing a dual-mechanism DME candidate and near-term funding and trial milestones.

Management framed fiscal 2027 around converting prior investments into cash flow, with minerals, operator activity, and improved field execution providing momentum.

Management framed Q4 as proof the transformation is scaling, with U.S. momentum, system execution, and disciplined customer targeting extending into FY27.

Management framed the quarter as evidence of durable value demand, while emphasizing prudent execution amid cost uncertainty and investment in international growth.

Management framed the quarter as an inflection point: conversion is complete, core growth remains strong, and the focus shifts to capturing synergies and returns.

Management framed Q3 as proof that years of scale-building are now converting into operating leverage, while stressing disciplined expansion amid volatile markets.

Management framed the half as an inflection point, pairing core post-quantum commercialization with a broader, investment-heavy quantum-security platform buildout.

Management framed Q2 as validation of Project Sunshine, with direct momentum and inventory discipline offsetting indirect-channel timing.

Management framed the quarter as an investment period ahead of REFIQ enterprise adoption and broader economics-sharing partnerships, without offering conversion timing.

Management framed the quarter as evidence of accelerating market expansion, improving unit economics, and commercial productivity supporting durable growth and operating leverage.

Management framed Kyverna as advancing a differentiated autoimmune CAR-T platform, with SPS filing and launch preparation the near-term priority.

Management framed Ero’s next phase around One Arrow transformation, deleveraging, operational technology, and Furnas-led growth.